等待開盤 08-22 09:30:00 美东时间
0.000
0.00%
Scottish craft brewer BrewDog, owned by Tilray Brands, Inc., has unveiled its 2026 Advent Calendar featuring 24 craft beers, including returning favorites and limited-edition seasonal brews. Priced at £51.99, pre-orders begin on September 7, 2026. The calendar includes a brand-new Harmony glass and three standout seasonal releases: Hoppy Christmas, Jingle Juice, and Cocoa Reserve. The design draws inspiration from BrewDog's bars and breweries. Ea...
08-18 11:30
700亿半导体“龙头”君正股份今起招股,一手入场费10383.68港元,IPO发行价较A股折价逾41%,广发基金、高毅等一众豪华基石抢购逾1.9亿美元>>
08-17 09:48
君正股份(03223.HK)于2026年8月17日至2026年8月20日招股,该公司拟全球发售3128.73万股H股,其中香港公开发售占10%,国际发售占90%,另有15%超额配股权。
08-17 07:00
Vertex, Inc. research highlights two key challenges—Defensibility Drift and CompOps Drag—that widen the Compliance Confidence Gap for enterprises managing indirect tax and compliance. These forces create a vicious cycle of complexity, reducing confidence in revenue reporting and leaving potential revenue on the table. Vertex's Decision-to-Defense approach addresses this by integrating compliance into the transaction lifecycle through four pillars...
07-30 14:05
投行Susquehanna最新研报指出,2026年新组装的个人电脑中,英特尔(INTC.US)与超微半导体(AMD.US)的旧款处理器占比显著上升。
07-15 11:20
Apollo-managed funds have completed the acquisitions of Emerald Holding, Inc. and Questex, LLC, forming a leading B2B experiential events and media platform. Paul Miller serves as CEO, Hervé Sedky as senior advisor, and new executives include Vince DiMaggio (CFO), Issa Jouaneh (COO), Kate Spellman (CCO), Kurt Nelson (CTO), and Sara Altschul (CLO). The companies will integrate over the coming months, aiming to accelerate growth and deliver greater...
07-14 20:05
TradingKey - On July 6, Intel (INTC) officially confirmed that it has raised the recommended retail prices for some of its consumer and server processors, with price increases ranging from dozens of dollars to over a thousand dollars.
07-06 09:17
今日重点评级关注:Needham:维持Artiva Biotherapeutics"买入"评级,目标价从18美元升至41美元;HC Wainwright & Co.:维持SAB Biotherapeutics"买入"评级,目标价从7美元升至10美元
05-13 11:46